Fulcrum Therapeutics, a Cambridge, Mass.-based biotech company focused on unlocking gene control mechanisms to develop small molecule therapies, has been established with $55m in Series A financing.
Third Rock Ventures, LLC, backed the company to further develop a cross-disciplinary product engine to identify and modulate gene regulatory targets core to disease across therapeutic areas, spearheaded by two initial programs in genetic diseases: Fragile X syndrome (FXS) and a form of muscular dystrophy called facioscapulohumeral muscular dystrophy (FSHD).
Fulcrum Therapeutics is led by President and Chief Executive Officer Robert J. Gould, Ph.D., while founders include:
– Michael Green, M.D., Ph.D.: University of Massachusetts Medical School; The Howard Hughes Medical Institute; National Academy of Sciences; providing expertise in gene regulation
– Danny Reinberg, Ph.D.: New York University School of Medicine; The Howard Hughes Medical Institute; National Academy of Sciences; providing expertise in chromatin structure and function
– Rudolf Jaenisch, M.D.: Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Institute of Medicine; National Academy of Sciences; providing expertise in stem cell biology
– Jeannie Lee, M.D., Ph.D.: Massachusetts General Hospital; Harvard Medical School; The Howard Hughes Medical Institute; National Academy of Sciences; providing expertise in gene regulation and X chromosome genetics
– Brad Bernstein, M.D., Ph.D.: Massachusetts General Hospital; Harvard Medical School; Broad Institute of MIT and Harvard; providing expertise in genome-wide characterization of gene regulation.
FinSMEs
21/07/2016